BR112022020320A2 - Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar i - Google Patents
Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar iInfo
- Publication number
- BR112022020320A2 BR112022020320A2 BR112022020320A BR112022020320A BR112022020320A2 BR 112022020320 A2 BR112022020320 A2 BR 112022020320A2 BR 112022020320 A BR112022020320 A BR 112022020320A BR 112022020320 A BR112022020320 A BR 112022020320A BR 112022020320 A2 BR112022020320 A2 BR 112022020320A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- patient
- endoxifen
- bipolar
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
MÉTODO PARA MANTER UMA CONCENTRAÇÃO TERAPEUTICAMENTE EFICAZ DE ENDOXIFENO PARA TRATAMENTO DE UM PACIENTE COM DISTÚRBIO BIPOLAR I. Trata-se de um método para manter uma concentração terapeuticamente eficaz de endoxifeno para o tratamento de paciente com distúrbio bipolar I. O método inclui administrar ao paciente uma dose de 2 mg a 16 mg de citrato de endoxifeno em um comprimido com revestimento entérico uma vez ao dia por pelo menos 21 dias. Adicionalmente, o dito método fornece um perfil de plasma in vivo desejável. O monitoramento de dose terapêutica não é necessário em um paciente submetido ao dito tratamento. Adicionalmente, o método fornece uma melhora significativa em mania avaliada pelas pontuações YMRS e MADRS no paciente submetido ao dito tratamento. Adicionalmente, o método fornece um tempo de resposta precoce do tratamento em pelo menos 2 dias e tempo de remissão que é no máximo 4 dias no paciente submetido ao dito tratamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008141P | 2020-04-10 | 2020-04-10 | |
| PCT/IB2021/052970 WO2021205402A1 (en) | 2020-04-10 | 2021-04-09 | Endoxifen for the treatment of bipolar i disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020320A2 true BR112022020320A2 (pt) | 2022-12-13 |
Family
ID=78005740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020320A BR112022020320A2 (pt) | 2020-04-10 | 2021-04-09 | Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar i |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11291640B2 (pt) |
| EP (1) | EP4132497A4 (pt) |
| CN (1) | CN115484941A (pt) |
| AU (1) | AU2021252229A1 (pt) |
| BR (1) | BR112022020320A2 (pt) |
| CA (1) | CA3177260A1 (pt) |
| MX (1) | MX2022012519A (pt) |
| WO (1) | WO2021205402A1 (pt) |
| ZA (1) | ZA202211308B (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| DK2101731T3 (en) | 2006-11-21 | 2018-04-16 | Jina Pharmaceuticals Inc | ENDOXIFEN FOR USING CANCER TREATMENT |
| US20120164075A1 (en) * | 2006-11-21 | 2012-06-28 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of mammalian diseases |
| WO2009120999A2 (en) | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
| KR101308258B1 (ko) * | 2010-10-15 | 2013-09-13 | 씨제이제일제당 (주) | 엔독시펜의 신규한 제조 방법 |
| IN2013MU00646A (pt) * | 2013-03-04 | 2015-06-26 | Intas Pharmaceuticals Ltd |
-
2021
- 2021-04-09 BR BR112022020320A patent/BR112022020320A2/pt unknown
- 2021-04-09 US US17/226,628 patent/US11291640B2/en active Active
- 2021-04-09 CN CN202180031809.9A patent/CN115484941A/zh active Pending
- 2021-04-09 MX MX2022012519A patent/MX2022012519A/es unknown
- 2021-04-09 EP EP21784506.4A patent/EP4132497A4/en active Pending
- 2021-04-09 AU AU2021252229A patent/AU2021252229A1/en active Pending
- 2021-04-09 CA CA3177260A patent/CA3177260A1/en active Pending
- 2021-04-09 WO PCT/IB2021/052970 patent/WO2021205402A1/en unknown
-
2022
- 2022-10-14 ZA ZA2022/11308A patent/ZA202211308B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210315843A1 (en) | 2021-10-14 |
| CA3177260A1 (en) | 2021-10-14 |
| EP4132497A1 (en) | 2023-02-15 |
| WO2021205402A1 (en) | 2021-10-14 |
| EP4132497A4 (en) | 2024-04-24 |
| MX2022012519A (es) | 2023-01-16 |
| CN115484941A (zh) | 2022-12-16 |
| ZA202211308B (en) | 2024-02-28 |
| AU2021252229A1 (en) | 2022-10-27 |
| US11291640B2 (en) | 2022-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020732A2 (pt) | Método de dosagem e tratamento de pacientes com um psicodélico, método para determinar uma dose de um psicodélico para um indivíduo, método para definir doses terapêuticas de um psicodélico em ensaios clínicos, método para tratar afecções psiquiátricas em um indivíduo, métodos de terapia, e método para monitorar indivíduos para depressão após tratamento com lsd | |
| Moore et al. | Head and thorax elevation during active compression decompression cardiopulmonary resuscitation with an impedance threshold device improves cerebral perfusion in a swine model of prolonged cardiac arrest | |
| BRPI0414455A (pt) | métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| Bogdanovski et al. | Hypoxia-inducible-factor-1 in trauma and critical care | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| BR112021024886A2 (pt) | Métodos de tratar a doença de fabry em pacientes com insuficiência renal | |
| Kushkestani et al. | The role of exercise and physical activity on aging-related diseases and geriatric syndromes | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| Wang et al. | The beneficial effect of electro-acupuncture given at PC6 (Neiguan-point) by the increase in cardiac transient outward K+ current channel which depends on the gene and protein expressions in artificially induced myocardial ischemia rats | |
| BR112022020320A2 (pt) | Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar i | |
| Brander et al. | Neural control of ventilation prevents both over-distension and de-recruitment of experimentally injured lungs | |
| Long et al. | Effects of adenosine triphosphate (atp) on early recovery after total knee arthroplasty (tka): a randomized, double-blind, controlled study | |
| Mathan et al. | Olanzapine-induced tender pitting pre-tibial edema | |
| BR112020013750A8 (pt) | Dispensação intranasal de olanzapina por dispositivo olfativo de precisão | |
| Pozzi et al. | Airway closure in patients with cardiogenic pulmonary edema as a cause of driving pressure overestimation: the “uncorking effect” | |
| Sahin et al. | Alterations of central hypercapnic respiratory response induced by acute central administration of serotonin re-uptake inhibitor, fluoxetine | |
| BR112022018315A2 (pt) | Regime para tratar a infecção por neisseria gonorrhoeae com gepotidacina | |
| BR112022020322A2 (pt) | Método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar i | |
| RU2020127436A (ru) | Композиция для лечения пациента, страдающего язвенным колитом, и применение композиции в качестве лекарственного средства | |
| Chen et al. | Clinical study on electroacupuncture for perimenopausal insomnia | |
| Nakamura et al. | Improvement of catatonia-induced rapid respiratory failure with electroconvulsive therapy: A case report | |
| CA3177266A1 (en) | Endoxifen for the treatment of bipolar i disorder | |
| Ali et al. | The Effect of Ketamine-Propofol Administration versus Propofol on Hemodynamic Stability during Induction and Intubation and Maintenance of Anesthesia | |
| Pantazopoulos et al. | Early corticosteroid initiation delays viral RNA clearance in respiratory secretions of COVID-19 patients |